... translation. The overall findings demonstrate the utility of phosphoproteomics to identify EC-protective agents to mitigate cardio-oncology side effects. Correspondence: Iris Z. Jaffe ( [email protected] ) 26 03 2024 27 07 2024 28 08 2024 29 08 2024 © 2024...

... cardiovascular sequelae. Therefore, a comprehensive baseline assessment and adequate monitoring by specialised cardio-oncology teams is essential in case these agents are used in combination, particularly in high-risk patients. This review summarises the mechanisms of action and treatment indications...

... cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic...

... by the participation of University of Minnesota in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society. Cardio-Oncology chemotherapy CYP1B1 Phytochemicals radiation therapy Cancer survivorship has significantly increased over the past two decades, thanks...

... inhibition in the progression of cancer-related cachexia and female sex and pre-existing comorbidities as independent risk factors for cardiac abnormalities after cancer treatment. cardiac arrhythmia cardio-oncology cardiotoxicity chemotherapy heart failure PI3Kα The phosphoinositide 3...

... of the Biochemical Society 2016 cardio-oncology chemotherapy heart failure Heart disease and cancer are the top two causes of mortality globally, accounting for 46.1% of deaths worldwide [ 1 ]. The incidence is projected to increase by 2030. Despite effective treatments for both aetiologies...